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HUMAN CANC(ERS differ widely in re-
sponse to chemotherapeutic agents. This is
the case for different tumours within one
histological group as well as for different
tumour types. Thus, rapidly growing acute
leukaemias and lymphomas generally re-
spond better to cytostatic agents than
more slowly growing tumours, such as
squamous cell and adenocarcinomas
(Zubrod, 1978; Malaise et al., 1973). The
observed differences in chemosensitivity
have, to a large extent, been attributed to
the concurrent differences in growth rates.
Here we present the unexpected finding
that in human melanomas growing s.c. in
athymic nuide mice, the response to DTIC
(Dacarbazine, NSC-45388), CCNU (Lomus-
tine, NSC-79037) and procarbazine (NSC-
7721.3) was in fact inversely related to the
growth rate of the xenografts.
In arecentstudyof6 human melanomas,
serially transplanted into nude mice
(BALB/c background) the early growth
rate measured in the range 30-60 mm3 was
found to be a characteristic and constant
property of the xenografts (Fodstad et al.,
1980a). The growth rates ofthe individual
tumours varied by more than 3-fold. This
opened the possibility of studying the
relationship between the growth rate of
the xenografts and their chemosensitivity.
We report here on the effect of DTIC,
CCNU and procarbazine, 3 of the most
effective drugs in the treatment of human
melanomas (Luce, 1972; Comis, 1976).
Accepted 7 Januiiary 1980
When the tumours had reached a mean
diameter of about 5 mm, groups of 8-10
tumour-bearing mice were treated with
200 mg/kg of procarbazine (i.p., Qd x 4),
150 mg/kg of DTIC (i.p., single dose) and
12*5 mg/kg of CCNU (i.p., single dose). In
separate experiments it was established
that these doses were close to toxic, but
non-lethal. Two vertical tumour dia-
meters measured twice weekly and the
tumour volume was obtained from the
formula: 7T/6 (mean diameter)3. For each
group of treated or control tumours the
mean time to double (TD) was calculated
and the growth delay that resulted from
the treatment was defined as
Growth delay =TDtreated -TDcontroi TDcontrol
As pointed out by Nowak et al. (1978) this
quantity may be regarded as an estimate
of the number of volume doubling times
saved by the treatment.
In the Figure the relationship between
the growth rate ofthe xenografts and their
response to the 3 drugs is given. Un-
expectedly, the response proved to be
inversely related to the observed growth
rates. Thus, for each drug, the number of
volume doubling times gained by the
treatment increased with the doubling
time of the untreated xenografts, i.e.
with decreasing growth rate. The high
correlation coefficients of the regression
lines indicate that the observed relation-
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FIGURE.-Relationsliip between growthi rate
of 6 malignant melanoma xenografts and
their response to CCNU, DTIC and pro-
carbazine. Groups of 8-10 mice carrying
the different xenografts were treated with
the drugs in doses given in the text. The
response is expressed on the ordinate as the
number of volume-doubling times gainied
by the treatment and the growth rate of
the untreated controls is given on the
abscissa.
ship is not fortuitous. The results are sup-
ported by experiments where the tumour
cells were treated in vitro and the number
of surviving clonogenic cells was measured
by a soft-agar technique, similar to that
ofCourtenay & Mills (1978). For each drug
the different tumours showed the same
relative sensitivity in vitro as found here
in vivo (Tveit et al., submitted).
An inverse relationship between growth
rate ofthe melanoma xenografts and their
chemosensitivity was not found for some
other drugs tested. In experiments re-
ported elsewhere (Fodstad et al., 1980b)
we studied the effect of the toxic
lectins abrin and ricin that have been
found to be as effective against various
human xenografts as some established
cytostatic drugs (Fodstad et al., 1977;
Pihl etal., 1979). We also tested vinblastine
which has been reported to give a response
in about 15% of human melanomas
(Comis, 1976). With these 3 agents a
clear response was obtained in most ofthe
xenografts. However, in these instances
the response of the different xenografts
showed no relationship to their growth
rates.
DTIC and CCNU are known to have a
stronger effect on proliferating than on
resting marrow cells (Valeriote & van
Putten, 1975). On this basis, it might be
anticipated that their effect would be
positively correlated with the growth rate
of the tumours. The inverse relationship
here found was therefore highly un-
expected.
The underlying mechanism of the data
here observed can only be revealed by
detailed kinetic studies. Whatever the
mechanism, our data show that the re-
lationship between growth rate and
chemosensitivity maybemore complicated
than hitherto assumed. If further data
corroborate the evidence now available
that the chemosensitivity of human xeno-
grafts reflects that of the tumours in situ
(Steel, 1978; Povlsen, 1978; Osieka et al.,
1977) the present results open the possi-
bility that measurements of growth para-
meters of the parent melanomas may be
of aid to clinicians in predicting the
response to at least some chemothera-
peutic agents.
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